What is the recommended management for functional esophageal disorders, including lifestyle modifications, a proton‑pump inhibitor trial, and low‑dose neuromodulator therapy?

Management of Functional Esophageal Disorders

For functional esophageal disorders, initiate lifestyle modifications and regular aerobic exercise, followed by a trial of low-dose PPI therapy (using the lowest effective dose), and if symptoms persist, escalate to low-dose tricyclic antidepressants (starting with amitriptyline 10 mg at bedtime, titrating to 30-50 mg daily) as second-line neuromodulator therapy. 1

Algorithmic Approach to Management

First-Line Treatment

Lifestyle Modifications:

• Strongly recommend regular aerobic exercise for all patients with functional esophageal disorders 1
• Avoid overly restrictive diets, as there is insufficient evidence for specialized dietary therapies including low-FODMAP diets 1
• Early dietitian involvement is critical to prevent malnutrition from excessive dietary restriction 1

Pharmacologic Therapy:

• Proton pump inhibitors (PPIs) are first-line pharmacologic treatment with strong evidence (high quality) 1
• Use the lowest dose that controls symptoms - there is no dose-response relationship 1
• Trial duration: 4-8 weeks initially 2
• If inadequate response, can increase to twice-daily dosing before declaring treatment failure 2
• PPIs are well-tolerated and clinicians should emphasize their safety 2

The 2022 British Society of Gastroenterology guidelines provide the most comprehensive and recent evidence, establishing PPIs as efficacious with strong recommendations based on high-quality evidence. This contrasts with older approaches that may have been more conservative about PPI use.

Second-Line Treatment: Neuromodulators

When to Escalate:

• Persistent symptoms after optimized PPI therapy (twice-daily dosing trial)
• Confirmed functional esophageal disorder on objective testing

Tricyclic Antidepressants (TCAs) - Preferred Second-Line:

• Strong recommendation with moderate quality evidence 1
• Specific dosing protocol:
  • Start amitriptyline 10 mg once daily at bedtime
  • Titrate slowly to maximum 30-50 mg once daily
  • Can be initiated in primary or secondary care
• Critical counseling points:
  • Explain these work as "gut-brain neuromodulators" not antidepressants
  • Address the brain-gut axis dysfunction underlying symptoms
  • Discuss side effect profile upfront (anticholinergic effects, sedation)

Recent 2024 meta-analysis data supports neuromodulators particularly for functional chest pain (52-71% symptom reduction) and globus (46-75% improvement, OR 6.30), though evidence remains mixed for functional heartburn and reflux hypersensitivity 3. However, a 2025 trial showed no short-term advantage of adding amitriptyline to PPI over PPI alone 4, highlighting that neuromodulators work best when functional disorders are confirmed rather than as empiric add-on therapy.

Alternative Neuromodulators:

• Antipsychotics (sulpiride 100 mg four times daily or levosulpiride 25 mg three times daily) may be efficacious but require careful explanation and counseling 1
• These are weaker recommendations compared to TCAs

Management of Severe or Refractory Disease

Multidisciplinary Approach Required:

• Involve specialized gastroenterology clinic with access to:
  • Interested clinician
  • Dietetic support
  • Gut-brain behavioral therapies
  • Access to efficacious medications 1

Critical Pitfalls to Avoid:

• Strongly avoid opioids - they cause iatrogenic harm without benefit 1
• Strongly avoid surgery - not indicated for functional disorders 1
• Screen for eating disorders including avoidant restrictive food intake disorder (ARFID) in patients with weight loss and food restriction 1

Important Clinical Nuances

Diagnostic Considerations:

• Before labeling as functional disorder, ensure H. pylori testing and eradication if positive 1
• Gastric emptying testing and 24-hour pH monitoring should NOT be done routinely 1
• A 2024 study found 83.2% of PPI-unresponsive reflux symptoms were actually functional esophageal disorders, not true GERD 5

Psychological Comorbidities:

• Functional esophageal disorders have strong associations with psychological distress and poor sleep quality 5
• Symptom severity correlates with degree of psychological comorbidity 5
• Address these factors as part of comprehensive management

Treatment Sequencing:

• The evidence does NOT support combining TCAs with PPIs as initial therapy 4
• Sequential escalation (lifestyle → PPI → neuromodulator) is the evidence-based approach
• Attempting to wean PPI to lowest effective dose is appropriate once symptoms controlled 2

Key Divergences in Evidence

While the 2022 BSG guidelines strongly recommend TCAs as second-line therapy based on moderate-quality evidence 1, a 2025 RCT found no advantage of adding amitriptyline to PPI over PPI alone in the short term 4. This apparent contradiction resolves when recognizing that neuromodulators work best in confirmed functional disorders after adequate PPI trial and objective testing, not as empiric add-on therapy. The BSG guidelines appropriately position neuromodulators as second-line after PPI optimization, which aligns with the pathophysiology of gut-brain axis dysfunction requiring targeted neuromodulation rather than acid suppression.